{"id":"lenvatinib-tislelizumab-gemcitabine-and-cisplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_fixedAt":"2026-03-30T11:56:40.316617","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and other kinases to inhibit angiogenesis and tumor growth. Tislelizumab is a humanized PD-1 inhibitor that restores anti-tumor immune responses by blocking the PD-1/PD-L1 axis. Gemcitabine and cisplatin are conventional chemotherapy agents that cause DNA damage and cell death. Together, this quadruple combination targets tumor vasculature, immune evasion, and direct cytotoxicity.","oneSentence":"This combination uses lenvatinib to inhibit multiple receptor tyrosine kinases, tislelizumab to block PD-1 immune checkpoints, and gemcitabine/cisplatin as cytotoxic chemotherapy agents to attack cancer cells through multiple pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:40.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 trial indication under investigation)"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT05532059","phase":"PHASE2","title":"Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-31","conditions":"Advanced Cholangiocarcinoma","enrollment":100},{"nctId":"NCT05823311","phase":"PHASE3","title":"Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-01","conditions":"Advanced Cholangiocarcinoma","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lenvatinib, tislelizumab, gemcitabine and cisplatin","genericName":"Lenvatinib, tislelizumab, gemcitabine and cisplatin","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses lenvatinib to inhibit multiple receptor tyrosine kinases, tislelizumab to block PD-1 immune checkpoints, and gemcitabine/cisplatin as cytotoxic chemotherapy agents to attack cancer cells through multiple pathways. Used for Advanced or metastatic solid tumors (Phase 3 trial indication under investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}